Evidence map›Paper›PMID 37658236›Full record

ReviewUrologie (Heidelberg, Germany)2023

[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].

Niklas Klümper, Markus Eckstein, Frank Kunath, Isabel Heidegger, Christoph Becker, Steffen Rausch, Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Niklas KlümperKlinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn (UKB), Bonn, Deutschland.
Markus EcksteinInstitut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
Frank KunathKlinik für Urologie und Kinderurologie, Klinikum Bayreuth GmbH, Bayreuth, Deutschland.
Isabel HeideggerDepartment für Urologie, Medizinische Universität Innsbruck, Innsbruck, Österreich.
Christoph BeckerRessort Forschungsförderung, Deutsche Gesellschaft für Urologie e. V., Düsseldorf, Deutschland. cbecker@dgu.de.
Steffen RauschKlinik für Urologie, Universitätsklinik Tübingen, Tübingen, Deutschland.
Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This compact review article highlights the background and importance of nectins in cancer therapy, focusing specifically on the antibody-drug conjugate enfortumab vedotin (EV) as a targeted treatment option for metastatic urothelial carcinoma. The evolving understanding of nectin-4 expression and its impact on EV therapy underscores the need for personalized approaches to ensure optimal patient outcomes. Further investigation into biomarker-guided therapies and prospective clinical trials are critical to refining patient selection and treatment strategies.

Indexed as

Carcinoma, Transitional CellImmunoconjugatesUrinary Bladder NeoplasmsCell Adhesion MoleculesHumansNectinsProspective StudiesCell Adhesion MoleculesImmunoconjugatesNectinsBiomarkersEnfortumab vedotin (EV)Nectin-4 expressionPatient selectionTargeted therapiesTreatment strategies

Identifiers

PMID37658236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.